

# **Prostate Immunotherapy and Research: Panel Discussion: MPCC 12 May, 2017**

**Glenn Bublely, MD, *Beth Israel Deaconess Medical Center, Moderator***  
**William G. Nelson, MD, PhD, *Johns Hopkins University School of  
Medicine***

**Susan F. Slovin, MD, PhD, *Memorial Sloan Kettering Cancer Center***

# In the beginning...


- 61 year old man presented with frequency, urgency, nocturia 4x
- Last PSA 0.8ng/dl at age 50
- DRE: 50g prostate, nontender
- PSA 8.0
- Biopsy: Gleason 4+3(7) adenocarcinoma  
[4 of 12 cores: 5-35% core involvement]

Imaging: bone/CT – negative

MRI pelvis: Enlarged prostate – no ECE

**Bladder**

**Prostate**





# Patient #1

- s/p robotic RRP: confirmed Gleason 4+3(7) in left mid/apex; 0/14 LN – negative
- Post RRP PSA nadir 0.2
- Imaging negative – salvage RT started
- PSA at 0.2, stable for 2 years
- PSA rising: 0.2, 0.5, 1.2, 2.0, 2.4, 4.1, 7
- Imaging suspicious for lesion in right SI joint
- Started CAB, now with continued rises in PSA
- Asymptomatic

BONE SCAN

MSKCC



R ANT L SS

L POST R

R ANT L

L POST R





C149  
W311


# Patient #1

**Is it time for:**

- a. Sip-T?
- b. Docetaxel?
- c. Checkpoint inhibition?
- d. Any combo of above?
- e. I don't know

# Vaccines in Prostate Cancer







- SKIN**
- **Dermatitis**
  - Erythema multiforme
  - Stevens Johnson syndrome
  - Toxic epidermal necrolysis
  - Vitiligo
  - Alopecia

- EYE**
- Uveitis
  - Iritis
  - Scleritis
  - Retinitis

- HEPATIC**
- **Transaminitis**
  - Hepatitis, autoimmune

- GASTROINTESTINAL (GI)**
- **Colitis**
  - Enterocolitis
  - Necrotizing colitis
  - GI perforation
  - Pancreatitis

- RENAL**
- Nephritis, autoimmune
  - Renal failure




- ENDOCRINE**
- Hypothyroidism
  - Hyperthyroidism
  - Adrenal insufficiency
  - Hypophysitis

- PULMONARY**
- **Pneumonitis**
  - Interstitial lung disease
  - Acute interstitial pneumonitis

- NEUROLOGIC**
- Autoimmune neuropathy
  - Demyelinating polyneuropathy
  - Guillain-Barre
  - Myasthenia gravis like syndrome

The more frequent serious complications appear in bold type.



**Parallel timelines and milestones of the development of therapies involving anti-CTLA-4 and anti-PD-1, from gene discovery through clinical development.**